new
data
describing
statistically
significant
results
phase
bright
trial
patients
autism
spectrum
disorder
asd
presented
virtual
joint
international
child
neurology
devon
globe
newswire
zynerba
pharmaceuticals
nasdaq
zyne
leader
innovative
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
presenting
poster
describing
data
phase
bright
tolerability
efficacy
study
administered
transdermal
gel
children
adolescents
autism
spectrum
disorder
trial
demonstrating
potential
improve
core
behavioral
symptoms
autism
administered
addition
stable
standard
care
children
adolescents
asd
open
label
data
presented
virtual
joint
international
child
neurology
congress
icnc
annual
child
neurology
society
cns
meeting
data
also
presented
oral
presentation
research
pipeline
new
findings
diagnostic
therapeutics
session
virtual
american
academy
child
adolescent
psychiatry
aacap
annual
meeting
friday
october
copy
poster
entitled
tolerability
efficacy
cannabidiol
cbd
transdermal
gel
children
adolescents
autism
spectrum
disorder
phase
study
bright
available
zynerba
corporate
website
http
publications
phase
bright
trial
provides
first
clinical
evidence
potential
zygel
improve
behavioral
symptomology
group
highly
symptomatic
pediatric
adolescent
patients
asd
said
helen
heussler
fracp
associate
professor
children
health
queensland
medical
director
child
development
principal
investigator
bright
trial
children
receiving
zygel
observed
changes
baseline
promising
particular
improvements
seen
core
symptoms
autism
specifically
assessed
autism
impact
measure
special
interest
though
open
label
results
compelling
look
forward
continuing
evaluation
zygel
asd
future
clinical
bright
phase
trial
exploratory
phase
study
evaluating
safety
tolerability
efficacy
zygel
children
adolescents
asd
years
old
study
enrolled
patients
clinical
global
impression
cgi
score
moderate
greater
aberrant
behavior
irritability
score
primary
objective
trial
evaluate
safety
tolerability
zygel
weeks
treatment
period
month
extension
period
secondary
objectives
comprised
evaluation
efficacy
zygel
treatment
symptoms
asd
including
measuring
parental
caregiver
stress
autism
impact
measure
aim
caregiver
reported
behavioral
problems
results
provided
poster
weeks
treatment
zygel
new
data
presented
today
include
patients
receiving
zygel
study
achieved
statistically
significant
improvements
compared
baseline
across
subscales
aim
designed
track
incremental
change
frequency
impact
core
asd
symptoms
atypical
behavior
p
communication
p
peer
interaction
p
repetitive
behavior
p
social
reciprocity
figure
statistically
significant
improvements
autism
impact
measure
scores
https
newsroom
attachmentng
addition
statistically
significant
improvements
compared
baseline
observed
week
treatment
zygel
autism
parenting
stress
index
p
figure
statistically
significant
improvements
apsi
https
newsroom
attachmentng
zynerba
also
measured
notable
improvements
behaviors
utilizing
qualitative
caregiver
behavioral
problems
survey
weeks
study
drug
clinically
meaningful
improvements
observed
majority
surveyed
caregivers
behavioral
social
emotional
behavioral
problems
figure
notable
improvements
qualitative
caregiver
behavioral
problems
survey
week
https
newsroom
attachmentng
authors
poster
concluded
bright
trial
provides
initial
evidence
suggesting
positive
profile
zygel
administered
addition
stable
standard
care
children
adolescents
asd
zygel
showed
improvement
asd
measures
aim
cgi
qualitative
caregiver
assessments
controlled
studies
warranted
population
results
supplement
topline
data
initially
disclosed
company
may
press
release
including
five
subscales
showed
statistically
significant
p
clinically
meaningful
improvements
weeks
treatment
baseline
results
efficacy
assessments
reinforce
results
demonstrated
including
mean
improvement
week
baseline
measured
parent
reported
anxiety
scale
asd
p
patients
assessed
much
improved
much
improved
week
measured
clinical
global
impression
improvement
scale
zygel
well
tolerated
trial
safety
profile
consistent
previously
released
data
zygel
clinical
trials
serious
severe
adverse
events
reported
zynerba
pharmaceuticals
zynerba
pharmaceuticals
leader
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
committed
improving
lives
patients
families
living
severe
chronic
health
conditions
including
fragile
x
syndrome
autism
spectrum
disorder
deletion
syndrome
heterogeneous
group
rare
epilepsies
known
developmental
epileptic
encephalopathies
learn
follow
us
twitter
zynerbapharma
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
company
current
expectations
management
expectations
therefore
statements
press
release
could
also
affected
risks
uncertainties
relating
number
factors
including
following
company
cash
cash
equivalents
may
sufficient
support
operating
plan
long
anticipated
company
ability
obtain
additional
funding
support
clinical
development
programs
results
cost
timing
company
clinical
development
programs
including
delays
clinical
trials
relating
enrollment
site
initiation
clinical
results
company
product
candidates
may
replicated
continue
occur
additional
trials
may
otherwise
support
development
specified
indication
actions
advice
food
drug
administration
foreign
regulatory
agencies
may
affect
design
initiation
timing
continuation
progress
clinical
trials
result
need
additional
clinical
trials
company
ability
obtain
maintain
regulatory
approval
product
candidates
labeling
approval
company
reliance
third
parties
assist
conducting
clinical
trials
product
candidates
delays
interruptions
failures
manufacture
supply
company
product
candidates
company
ability
commercialize
product
candidates
size
growth
potential
markets
company
product
candidates
company
ability
service
markets
company
ability
develop
sales
marketing
capabilities
whether
alone
potential
future
collaborators
rate
degree
market
acceptance
company
product
candidates
company
expectations
regarding
ability
obtain
adequately
maintain
sufficient
intellectual
property
protection
product
candidates
timing
outcome
current
future
legal
proceedings
extent
health
epidemics
outbreaks
communicable
diseases
including
could
disrupt
operations
adversely
affect
business
financial
conditions
list
exhaustive
risks
described
company
periodic
reports
including
annual
report
form
quarterly
reports
form
current
reports
form
filed
furnished
securities
exchange
commission
available
statements
company
makes
press
release
speak
date
press
release
company
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
zynerba
contact
roberts
vp
investor
relations
corporate
communications
robertsw
media
contact
molly
devlin
evoke
kyne
